Origin of metastable oligomers and their effects on amyloid fibril self-assembly† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc01479e

Simultaneous analysis of oligomer and fibril assembly kinetics reveals inhibitory effects of metastable oligomers on amyloid fibril formation.

[1]  S. Prusiner,et al.  A long‐lived Aβ oligomer resistant to fibrillization , 2018, Biopolymers.

[2]  M. Hedenqvist,et al.  On the role of peptide hydrolysis for fibrillation kinetics and amyloid fibril morphology , 2018, RSC advances.

[3]  Alexander K. Buell,et al.  Scaling behaviour and rate-determining steps in filamentous self-assembly , 2017, Chemical science.

[4]  M. Wolff,et al.  Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution , 2017, Scientific Reports.

[5]  C. Dobson,et al.  Modulation of electrostatic interactions to reveal a reaction network unifying the aggregation behaviour of the Aβ42 peptide and its variants† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00215g Click here for additional data file. , 2017, Chemical science.

[6]  S. Uddin,et al.  A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics. , 2016, Journal of the American Chemical Society.

[7]  D. Walsh,et al.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer. , 2016, Biochemistry.

[8]  Yujin E. Kim,et al.  Soluble Oligomers of PolyQ-Expanded Huntingtin Target a Multiplicity of Key Cellular Factors. , 2016, Molecular cell.

[9]  Tuomas P. J. Knowles,et al.  Quantitative analysis of intrinsic and extrinsic factors in the aggregation mechanism of Alzheimer-associated Aβ-peptide , 2016, Scientific Reports.

[10]  Michele Vendruscolo,et al.  Molecular mechanisms of protein aggregation from global fitting of kinetic models , 2016, Nature Protocols.

[11]  Marco Y. Hein,et al.  A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation , 2015, Cell.

[12]  Judianne Davis,et al.  Mechanism of Nucleated Conformational Conversion of Aβ42. , 2015, Biochemistry.

[13]  K. Zahs,et al.  Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration. , 2015, Cell reports.

[14]  J. Kardos,et al.  Supersaturation-limited and Unlimited Phase Transitions Compete to Produce the Pathway Complexity in Amyloid Fibrillation* , 2015, The Journal of Biological Chemistry.

[15]  S. Radford,et al.  pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers , 2015, Proceedings of the National Academy of Sciences.

[16]  Ryan J. Morris,et al.  Competition between primary nucleation and autocatalysis in amyloid fibril self-assembly. , 2015, Biophysical journal.

[17]  J. Schmit,et al.  Stable, Metastable, and Kinetically Trapped Amyloid Aggregate Phases , 2014, Biomacromolecules.

[18]  Yun-Ru Chen,et al.  Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients , 2014, Nature Communications.

[19]  M. Rowan,et al.  Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. , 2014, The Biochemical journal.

[20]  J. Cirrito,et al.  Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease , 2014, The Journal of Neuroscience.

[21]  R. Pappu,et al.  Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation , 2013, Proceedings of the National Academy of Sciences.

[22]  M. Wolff,et al.  The Off-rate of Monomers Dissociating from Amyloid-β Protofibrils* , 2013, The Journal of Biological Chemistry.

[23]  S. Westerheide,et al.  Structural fingerprints and their evolution during oligomeric vs. oligomer-free amyloid fibril growth. , 2013, The Journal of chemical physics.

[24]  W. Surewicz,et al.  Crystal structure of a human prion protein fragment reveals a motif for oligomer formation. , 2013, Journal of the American Chemical Society.

[25]  Michele Vendruscolo,et al.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.

[26]  Taru Deva,et al.  Off-pathway aggregation can inhibit fibrillation at high protein concentrations. , 2013, Biochimica et biophysica acta.

[27]  Suneil K. Kalia,et al.  α‐Synuclein oligomers and clinical implications for Parkinson disease , 2013, Annals of neurology.

[28]  R. Kayed,et al.  Molecular mechanisms of amyloid oligomers toxicity. , 2012, Journal of Alzheimer's disease : JAD.

[29]  M. Saraiva,et al.  Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils , 2012, PloS one.

[30]  M. Göbel,et al.  Laser-induced liquid bead ion desorption mass spectrometry: an approach to precisely monitor the oligomerization of the β-amyloid peptide. , 2012, Analytical chemistry.

[31]  D. Eisenberg,et al.  Toxic fibrillar oligomers of amyloid-β have cross-β structure , 2012, Proceedings of the National Academy of Sciences.

[32]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[33]  David Eisenberg,et al.  Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.

[34]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[35]  Michele Vendruscolo,et al.  Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. , 2011, The Journal of chemical physics.

[36]  J. Kelly,et al.  Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers , 2011, Nature chemical biology.

[37]  S. Hill,et al.  Spatial Extent of Charge Repulsion Regulates Assembly Pathways for Lysozyme Amyloid Fibrils , 2011, PloS one.

[38]  Shinichiro Nakamura,et al.  Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses* , 2011, The Journal of Biological Chemistry.

[39]  Yuguang Mu,et al.  The Molecular Basis of Distinct Aggregation Pathways of Islet Amyloid Polypeptide* , 2010, The Journal of Biological Chemistry.

[40]  T. Wyttenbach,et al.  Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to beta-sheet in amyloid fibril formation , 2010, Nature chemistry.

[41]  R. Kayed,et al.  Preparation and characterization of neurotoxic tau oligomers. , 2010, Biochemistry.

[42]  N. Ferguson,et al.  Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.

[43]  Christopher M. Dobson,et al.  The Non-Core Regions of Human Lysozyme Amyloid Fibrils Influence Cytotoxicity , 2010, Journal of molecular biology.

[44]  Gengfu Xiao,et al.  Macromolecular crowding converts the human recombinant PrPc to the soluble neurotoxic β‐oligomers , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  K. Matsuzaki,et al.  A disulfide-linked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation. , 2010, Biochemistry.

[46]  C. Dobson,et al.  Sequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In Vivo , 2010, PLoS biology.

[47]  Tuomas P. J. Knowles,et al.  An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.

[48]  Jin-Moo Lee,et al.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide , 2009, Proceedings of the National Academy of Sciences.

[49]  S. Radford,et al.  Fibril Fragmentation Enhances Amyloid Cytotoxicity*♦ , 2009, The Journal of Biological Chemistry.

[50]  D. Teplow,et al.  Structure-neurotoxicity relationships of amyloid β-protein oligomers , 2009, Neuroscience Research.

[51]  Yves F Dufrêne,et al.  Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. , 2009, The Biochemical journal.

[52]  C. Robinson,et al.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. , 2009, Nature chemistry.

[53]  S. Hill,et al.  Amyloid protofibrils of lysozyme nucleate and grow via oligomer fusion. , 2009, Biophysical journal.

[54]  D. Teplow,et al.  Amyloid β-Protein Assembly and Alzheimer Disease* , 2009, Journal of Biological Chemistry.

[55]  V. Uversky,et al.  Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. , 2008, Journal of molecular biology.

[56]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[57]  E. Powers,et al.  Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. , 2008, Biophysical journal.

[58]  Sheena E. Radford,et al.  Folding versus aggregation: Polypeptide conformations on competing pathways , 2008, Archives of biochemistry and biophysics.

[59]  J. Houzel,et al.  Soluble oligomers from a non‐disease related protein mimic Aβ‐induced tau hyperphosphorylation and neurodegeneration , 2007, Journal of neurochemistry.

[60]  Atanas V Koulov,et al.  Functional amyloid--from bacteria to humans. , 2007, Trends in biochemical sciences.

[61]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[62]  R. Wetzel,et al.  Polymorphism in the intermediates and products of amyloid assembly. , 2007, Current opinion in structural biology.

[63]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[64]  O. Bocharova,et al.  Amyloid Fibrils of Mammalian Prion Protein Are Highly Toxic to Cultured Cells and Primary Neurons* , 2006, Journal of Biological Chemistry.

[65]  A. Darinskas,et al.  Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid? , 2006, Biochemistry (Moscow).

[66]  S. Radford,et al.  Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. , 2005, Journal of molecular biology.

[67]  Hai Lin,et al.  Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Raimon Sabaté,et al.  Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. , 2005, The journal of physical chemistry. B.

[69]  M. Stefani.  Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. , 2004, Biochimica et biophysica acta.

[70]  M. Fändrich,et al.  FTIR reveals structural differences between native β‐sheet proteins and amyloid fibrils , 2004, Protein science : a publication of the Protein Society.

[71]  R. Kayed,et al.  Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.

[72]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[73]  J. Kelly,et al.  Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  E. Rhoades,et al.  Micelle formation by a fragment of human islet amyloid polypeptide. , 2003, Biophysical journal.

[75]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[76]  M U Palma,et al.  Time scale of protein aggregation dictated by liquid‐liquid demixing , 2003, Proteins.

[77]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[78]  Christopher M Dobson,et al.  The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation , 2002, The EMBO journal.

[79]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[80]  V. Uversky,et al.  Elucidation of the Molecular Mechanism during the Early Events in Immunoglobulin Light Chain Amyloid Fibrillation , 2002, The Journal of Biological Chemistry.

[81]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[82]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[83]  S. Lindquist,et al.  Nucleated conformational conversion and the replication of conformational information by a prion determinant. , 2000, Science.

[84]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[86]  P. Lansbury,et al.  Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  C. Blake,et al.  From the globular to the fibrous state: protein structure and structural conversion in amyloid formation , 1998, Quarterly Reviews of Biophysics.

[89]  A. Fink.  Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.

[90]  J. Buxbaum.  The systemic amyloidoses , 1998, Current opinion in rheumatology.

[91]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[92]  Franz Rosenberger,et al.  Liquid-Liquid Phase Separation in Supersaturated Lysozyme Solutions and Associated Precipitate Formation/Crystallization , 1997 .

[93]  B. Hyman,et al.  The Neuropathological Diagnosis of Alzheimer’s Disease: Clinical-Pathological Studies , 1997, Neurobiology of Aging.

[94]  D. Dickson,et al.  Neuropathological Diagnosis of Alzheimer’s Disease: A Perspective from Longitudinal Clinicopathological Studies , 1997, Neurobiology of Aging.

[95]  D. Kirschner,et al.  On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  C. Glabe,et al.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.

[97]  D. Booth,et al.  Human lysozyme gene mutations cause hereditary systemic amyloidosis , 1993, Nature.